Lv43
470 积分 2022-02-22 加入
Updated Overall Survival Analysis From IMpower110: Atezolizumab Versus Platinum-Based Chemotherapy in Treatment-Naive Programmed Death-Ligand 1–Selected NSCLC
8天前
已完结
Five-Year Survival Outcomes With Atezolizumab After Chemotherapy in Resected Stage IB-IIIA Non–Small Cell Lung Cancer (IMpower010): An Open-Label, Randomized, Phase III Trial
8天前
已完结
Five Year Survival Update From KEYNOTE-010: Pembrolizumab Versus Docetaxel for Previously Treated, Programmed Death-Ligand 1–Positive Advanced NSCLC
8天前
已完结
Effects of interventions for enhancing resilience in cancer patients: A systematic review and network meta-analysis
11天前
已完结
The Role of Maintenance Strategies in Metastatic Colorectal Cancer
11天前
已完结
Network Meta-Analysis
11天前
已完结
Comparison of First-Line Treatments for Patients With Extensive-Stage Small Cell Lung Cancer
11天前
已完结
Comparative safety of immune checkpoint inhibitors in cancer: systematic review and network meta-analysis
11天前
已完结
Immunotherapy for advanced-stage squamous cell lung cancer: the state of the art and outstanding questions
11天前
已完结
Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
12天前
已完结
皖公网安备34019202002308
